Standout Papers

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR... 2016 2026 2019 2022 2.1k
  1. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial (2016)
    Louis Fehrenbacher, Alexander I. Spira et al. The Lancet

Immediate Impact

2 by Nobel laureates 26 from Science/Nature 62 standout
Sub-graph 1 of 21

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy
2023 StandoutNature
1 intermediate paper

Works of C. Lewanski being referenced

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout

Author Peers

Author Last Decade Papers Cites
C. Lewanski 2389 1634 383 579 41 2.9k
Michael McCleod 2465 1666 269 335 44 2.9k
Wei Zou 2996 1959 662 819 56 3.5k
Maen Hussein 2440 1625 216 618 45 2.7k
Alexander I. Spira 2172 1327 379 627 19 2.5k
Ariel López-Chávez 2711 1853 452 562 41 3.6k
Hui Yu 1790 923 328 640 39 2.3k
William J. Geese 2415 1375 447 608 42 2.9k
Daniel Waterkamp 3439 1869 525 800 38 3.8k
Tien Hoang 1740 1410 224 270 65 2.3k
Davey B. Daniel 2170 2023 656 353 80 3.2k

All Works

Loading papers...

Rankless by CCL
2026